Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "Supernus Pharmaceuticals, Inc." (SUPN) Report Updated: Sep 24, 2017 | Print This Page

Get more stock ratings by Louis Navellier

"Supernus Pharmaceuticals, Inc." (SUPN)

Rating: Hold Volatility: Moderate
Total Grade: C Industry: Pharmaceuticals

Stock Analysis

Rating: Monthly View

September October November December January February March April May June July August

Rating: Weekly View

This Week: C down downgrade
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

"Supernus Pharmaceuticals, Inc."© quotemedia

Company Profile

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its marketed products include Oxtellar XR, an extended-release oxcarbazepine and Trokendi XR, an extended-release topiramate, which are neurology products used for the treatment of epilepsy. The company products also comprise SPN-810, a molindone hydrochloride that has completed Phase II clinical trials for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIa clinical trials for the treatment of ADHD. In addition, it is developing SPN-809, a viloxazine hydrochloride as a once-daily product candidate for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.